Royalties Grow as New Drug Sales Expand... Stock Loans for Medium- to Long-Term Investing
Domestic pharmaceutical companies are improving their earnings mix on the back of growing global sales of a new lung cancer drug. As royalties tied to overseas sales are added to their existing pharmaceutical businesses, recurring revenue is accounting for a larger share of earnings. Analysts expect operating profit to increase year-on-year even without the inclusion of large one-time technology fees, and are focusing on profitability improvements driven by sales.
The subcutaneous formulation of a combination therapy is also seen as a factor that could affect prescription growth going forward. This is because its use in combination therapies is expected to expand as administration becomes more convenient and insurance claims procedures improve. Development of follow-on drugs is also underway, making it important to monitor global sales trends, the contribution of royalties to earnings, and clinical progress. Separately assessing growth in recurring revenue and R&D results could help identify medium- to long-term investment opportunities in the pharmaceutical sector.
Meanwhile, All New Stock Loan is drawing attention with a range of interest rate terms and products, including offerings in the 5% range per year. It is seen as one option for investors seeking greater flexibility in responding to investment timing amid rapidly changing market conditions.
- All New Stock Loan launches an industry-lowest-rate product in the 5% range per year!
All New Stock Loan has launched a securities-linked credit product with an industry-lowest interest rate in the 5% range per year, enabling investors to use stock loans without undue burden. The product can be used both to purchase stocks and to refinance brokerage firms' margin and credit loans. Investors can access up to four times their own capital, with no difference based on credit rating. Investors using alternative trading systems (NXT) can also use the product.
Investors who would like to learn more about All New Stock Loan can contact the customer service center at 1599-8666 to speak with a professional counselor at any time, regardless of whether they qualify for a loan.
○ Industry-lowest-rate product launched, with interest rates in the 5% range per year!
○ ETF trading available
○ Use up to four times your own capital for stock investments!
○ Same-day refinancing of brokerage credit and margin loans available!
○ Trading through alternative trading systems (NXT) available
○ OK for stocks that were difficult to purchase using existing brokerage credit or stock loans!
* All New Stock Loan Customer Service Center: 1599-8666
Link: https://allnewstockloan.co.kr
SK Square, Samkee Energy Solution, HPSP, Hanwha Solutions, Hansun Engineering
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
※ This content is not affiliated with the editorial policies of The Asia Business Daily. The information provider bears all responsibility.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.